January 7, 2008 - Imaging for early cardiovascular disease that causes heart attack and stroke is the focus of the High ...
January 7, 2008 - Boston Scientific Corp. has completed the sale of its Cardiac Surgery and Vascular Surgery businesses ...
January 7, 2008 - Osiris Therapeutics Inc. has reclaimed sole worldwide rights to cardiovascular indications for Prochymal and terminated its development and commercialization agreement with Boston Scientific Corp. in order to provide Osiris with the flexibility to enter more strategically beneficial relationships.
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
January 7, 2008 – Patients with atrial flutter and atrial fibrillation may require additional sites of ablation to ...
January 7, 2008 - Abiomed Inc. has rolled out a new Portable Circulatory Support Driver for both in-hospital and out-of ...
January 3, 2008 - A study reported in the Jan. 3 New England Journal of Medicine found that one third of patients who ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
January 3, 2008 - A patient’s physical activity status is a significant and robust predictor of all-cause mortality in ...
January 3, 2008 - A modular stent graft that inserts multiple, caudally-directed branches to the visceral arteries to ...
January 3, 2008 - Medical Simulation Corp. and Edwards Lifesciences Corp. will launch the Edwards SAPIEN Transcatheter ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
January 3, 2008 – Abiomed Inc. selected Tufts-New England Medical Center (Tufts-NEMC) as a “Center of Excellence” for ...
January 2, 2008 – Allergic-like reactions to gadolinium-containing contrast injections in adults and pediatric patients ...
December 28, 2007 - The data converter and amplifiers market for portable imaging systems will reach $582.7 million in ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 29, 2007 - Boston Scientific Corp. received CE Mark approval for its LIVIAN cardiac resynchronization therapy defibrillator (CRT-D), which treats heart failure and is designed to help protect patients at risk of sudden cardiac death by monitoring heartbeats in heart failure patients and delivering small electrical impulses that may improve the heart’s pumping ability.
December 21, 2007 - Edwards Lifesciences Corp. (Edwards) has completed its acquisition of certain assets of the ...
December 26, 2007 - Boston Scientific Corp. announced its TAXUS Liberte paclitaxel-eluting coronary stent system has ...